[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.211.168.204. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Viewpoint
October 2014

Proposed US Food and Drug Administration Guidance for Industry on Distributing Medical Publications About the Risks of Prescription Drugs and Biological ProductsA Misguided Approach

Author Affiliations
  • 1Public Citizen’s Health Research Group, Washington, DC
JAMA Intern Med. 2014;174(10):1543-1544. doi:10.1001/jamainternmed.2014.4547

In June 2014, the US Food and Drug Administration (FDA) for the first time issued draft guidance for the pharmaceutical industry on distributing scientific and medical publications about the risks of approved prescription drugs and biological products.1 In my view, the draft guidance, which is open for public comment until August 25, 2014,2 has the potential to undermine the FDA’s drug safety laws and regulations and should be changed.

First Page Preview View Large
First page PDF preview
First page PDF preview
×